Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
463
-
Total 13F shares, excl. options
-
133M
-
Shares change
-
+16.6M
-
Total reported value, excl. options
-
$26.6B
-
Value change
-
+$3.4B
-
Put/Call ratio
-
0.56
-
Number of buys
-
268
-
Number of sells
-
-179
-
Price
-
$200.16
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q3 2022
555 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2022.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 463 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 133M shares
.
Largest 10 shareholders include Nuveen Asset Management, LLC (16.6M shares), Capital World Investors (13.9M shares), FMR LLC (12.9M shares), VANGUARD GROUP INC (11.1M shares), BAILLIE GIFFORD & CO (9.51M shares), BlackRock Inc. (7.67M shares), WELLINGTON MANAGEMENT GROUP LLP (5.95M shares), Dodge & Cox (4.89M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.72M shares), and T. Rowe Price Investment Management, Inc. (3.19M shares).
This table shows the top 463 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.